A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers

Trial Profile

A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Selumetinib (Primary) ; Vistusertib (Primary)
  • Indications Breast cancer; Colorectal cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms TORCMEK
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results assessing optimal doses and schedule of vistusertib and selumetinib when given in combination, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top